Relay Therapeutics Inc (RLAY)

Feb 10, 2026

Relay Therapeutics stock hits 52-week high at $9.16 By Investing.com - Investing.com South Africa

Feb 10, 2026

Feb 09, 2026

Relay Therapeutics (NASDAQ:RLAY) Sets New 12-Month HighTime to Buy? - MarketBeat

Feb 09, 2026

Feb 09, 2026

Relay Therapeutics stock hits 52-week high at $9.16 - Investing.com

Feb 09, 2026

Feb 08, 2026

Assessing Relay Therapeutics (RLAY) Valuation After Recent Share Price Momentum And Price To Book Discount - Sahm

Feb 08, 2026

Feb 07, 2026

Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib - Yahoo Finance

Feb 07, 2026

Feb 06, 2026

Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run - The Globe and Mail

Feb 06, 2026

Feb 05, 2026

$207B Market Shift: The Race for Fast Track Approval in Oncology - Investing News Network

Feb 05, 2026

Feb 05, 2026

$207B Market Shift: The Race for Fast Track Approval in Oncology - Benzinga

Feb 05, 2026

Feb 04, 2026

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - Investing News Network

Feb 04, 2026

Feb 03, 2026

Relay Thera’s zovegalisib wins ‘Breakthrough’ status from FDA - The Pharma Letter

Feb 03, 2026

Feb 03, 2026

Relay Therapeutics announces Zovegalisib granted therapy designation by FDA for PIK3CA-mutant - marketscreener.com

Feb 03, 2026

Feb 03, 2026

Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com South Africa

Feb 03, 2026

Feb 03, 2026

Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status - Investing.com

Feb 03, 2026

Feb 03, 2026

Relay Therapeutics Announces Breakthrough Therapy Designation for Zovegalisib - TradingView

Feb 03, 2026

Feb 03, 2026

Relay Therapeutics Announces Zovegalisib Granted - GlobeNewswire

Feb 03, 2026

Feb 03, 2026

FDA fast-tracks Relay drug for hard-to-treat advanced breast cancer - Stock Titan

Feb 03, 2026

Feb 03, 2026

Aug Retail: Can Relay Therapeutics Inc sustain its profitabilityProfit Target & Step-by-Step Swing Trade Plans - baoquankhu1.vn

Feb 03, 2026

Feb 02, 2026

Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Finviz

Feb 02, 2026

Feb 02, 2026

Relay Therapeutics (NASDAQ:RLAY) Shares Up 7.2%Here's Why - MarketBeat

Feb 02, 2026

Feb 02, 2026

Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Yahoo Finance

Feb 02, 2026

Feb 02, 2026

What Relay Therapeutics (RLAY)'s Zovegalisib Data and Insider Sales Mean For Shareholders - Sahm

Feb 02, 2026

Feb 01, 2026

Rate Cut: Is Relay Therapeutics Inc a speculative investmentPortfolio Gains Report & Consistent Profit Alerts - baoquankhu1.vn

Feb 01, 2026

Jan 31, 2026

Movement Recap: Will Relay Therapeutics Inc benefit from government policyWeekly Profit Recap & Free Technical Pattern Based Buy Signals - baoquankhu1.vn

Jan 31, 2026

Jan 30, 2026

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring an 88.66% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Jan 30, 2026

Jan 30, 2026

Relay Therapeutics (RLAY) Valuation Check After Analyst Upgrades And Zovegalisib Breast Cancer Data - Sahm

Jan 30, 2026

Jan 30, 2026

Relay Therapeutics president sells $166k in RLAY stock By Investing.com - Investing.com Australia

Jan 30, 2026

Jan 29, 2026

Moving Averages: Is Trex Company Inc stock a buy or sellTrade Analysis Summary & Advanced Swing Trade Entry Alerts - baoquankhu1.vn

Jan 29, 2026

Jan 29, 2026

Guidance Update: Can Relay Therapeutics Inc reach all time highs this year - baoquankhu1.vn

Jan 29, 2026

Jan 29, 2026

Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 2,686 Shares - MarketBeat

Jan 29, 2026

Jan 29, 2026

Relay Therapeutics (NASDAQ:RLAY) Insider Sells $11,441.30 in Stock - MarketBeat

Jan 29, 2026

Jan 29, 2026

Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CFO Sells 1,695 Shares of Stock - MarketBeat

Jan 29, 2026

Jan 29, 2026

Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 11,684 Shares of Stock - MarketBeat

Jan 29, 2026

Jan 29, 2026

Thomas Catinazzo Sells 13,820 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock - MarketBeat

Jan 29, 2026

Jan 29, 2026

Rahmer Peter, chief corporate development officer at Relay Therapeutics, sells $100k in shares - Investing.com Canada

Jan 29, 2026

Jan 29, 2026

Relay Therapeutics president sells $166k in RLAY stock - Investing.com

Jan 29, 2026

Jan 28, 2026

Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 6.7%Should You Sell? - MarketBeat

Jan 28, 2026

Jan 28, 2026

Trend Recap: What is the Moat Score of REGNJuly 2025 Setups & Technical Pattern Alert System - baoquankhu1.vn

Jan 28, 2026

Jan 28, 2026

Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism (NASDAQ:RLAY) - Seeking Alpha

Jan 28, 2026

Jan 27, 2026

Relay Therapeutics shares climb after Oppenheimer lifts rating - MSN

Jan 27, 2026

Jan 27, 2026

Relay Therapeutics (NASDAQ:RLAY) Trading Up 8.4%Here's Why - MarketBeat

Jan 27, 2026

Jan 27, 2026

Oppenheimer Upgrades Relay Therapeutics (RLAY) with Positive Out - GuruFocus

Jan 27, 2026

Jan 26, 2026

Oppenheimer Upgrades Relay Therapeutics (RLAY) - Nasdaq

Jan 26, 2026

Jan 26, 2026

Oppenheimer upgrades Relay Therapeutics stock rating on gedatolisib concerns By Investing.com - Investing.com Canada

Jan 26, 2026

Jan 26, 2026

Relay Therapeutics (RLAY) Upgraded by Oppenheimer, Price Target Set at $14.00 | RLAY Stock News - GuruFocus

Jan 26, 2026

Jan 26, 2026

Relay Therapeutics stock rises after Oppenheimer upgrade By Investing.com - Investing.com Nigeria

Jan 26, 2026

Jan 26, 2026

Relay Therapeutics stock rises after Oppenheimer upgrade - Investing.com

Jan 26, 2026